Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
764.440.02%
QQQ
715.040.02%
BTC/USD
77420.500.2754%
DIA
525.910.02%
GLD
398.290.12%
TLT
80.930.07%

Bicara Therapeutics Inc (BCAX) Stock Price, Quote, News & History

BCAXNASDAQ
Trade with Public
Trade with Public
$22.81
-0.29-1.26%
At close: Sep 11, 5:00 PM EST
$22.81
N/A
After Hours: 4:33 PM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompareOptionsStock Report

Bicara Therapeutics (BCAX) Stock Price, Quote, News & History | Benzinga

Key Statistics

Open
$23.29
Close
$22.81
Volume / Avg.
471.46K / 719.63K
Day Range
$22.40 - $24.23
52 Wk Range
10.30 - 30.99
Market Cap
$1.51B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
39
Short Interest
22.83%
Days to Cover
22.08

Recent Bicara Therapeutics Inc News

Bicara Therapeutics Analysts Raise Their Forecasts After Q2 Results

Bicara Therapeutics (BCAX) reported a narrower-than-expected loss in Q2. Analysts raised price targets, but shares dipped 14.3% to $23.76. #BCAX #earnings
Avi Kapoor

Bicara Therapeutics To Rally Around 121%? Here Are 10 Top Analyst Forecasts For Tuesday

Top analysts changed outlook on top names. See all changes on analyst ratings page. BTIG & HCW cut price targets, Needham & BMO raised, Baird bcut.
Avi Kapoor

Bicara Therapeutics Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Bicara Therapeutics Inc (BCAX) to release Q4 earnings on March 30. Expected loss of 65 cents/share. Analysts have mixed ratings and price targets.
Avi Kapoor

4 Biotech Stocks Seeing Explosive Momentum Gains

The SPDR S&P Biotech ETF (ARCA:XBI) is up more than 40% over the past six months and is on the verge of breaking out. Here's a look at several momentum standouts in the biotech space that appear to be rapidly gaining strength.
Dylan Berman

Bicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?

Bicara Therapeutics Inc. (NASDAQ: BCAX) shares are trading lower Friday following the release of updated interim data.
Vaishali Prayag

Financials

Quarterly
Annual
Name
Revenue
Change
Gross
Change
EBITDA
Change
EBIT
Change
Earnings
Change

Cash Flows

Operating Cash Flow (TTM)
-134.85M
Investing Cash Flow (TTM)
-402.50M
Financing Cash Flow (TTM)
197.34M
Free Cash Flow (TTM)
-135.25M
Capital Expenditure (TTM)
-
Net Change in Cash (TTM)
-340.01M

Analyst Trends and Forecast

3
2
Mar
2
1
May
4
3
Aug
Buy
Hold
Sell
Strong Sell

Analyst Rating and Forecast

12345
3.8
Buy
Strong Buy
Buy
Hold
Sell
Strong Sell

Valuation Metrics

Enterprise Value
$1.02B
PE Ratio (TTM)
-
PE Ratio (FWD)
-
PEG Ratio (TTM)
-
PS Ratio (TTM)
-
PB Ratio (TTM)
3.26
Earnings Yield % (TTM)
-13.29%
Earnings Yield % (FWD)
-
EV / EBITDA (TTM)
-
Price / EBITDA (TTM)
-
Price / Free Cash Flow (TTM)
-
Book Value / Share
$7.08

Company Debt

Total Debt
-
LT Debt
-
LT Debt Issuance (TTM)
-
LT Debt Repayment (TTM)
-
Total Cash
$96.60M
Debt to Equity
0.00
Issuance of Debt (TTM)
-
Repayment of Debt (TTM)
-

Key Statistics

Open
$23.29
Close
$22.81
Volume / Avg.
471.46K / 719.63K
Day Range
$22.40 - $24.23
52 Wk Range
10.30 - 30.99
Market Cap
$1.51B
P/E Ratio
-
Dividend Yield
-
Exchange
NASDAQ
RSI
39
Short Interest
22.83%
Days to Cover
22.08

About

Sector
Health Care
Industry
Biotechnology
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets,...
Show More
Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Compare

EPS worse than industry
Earnings Per Share
EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

FAQ

Q

How do I buy Bicara Therapeutics (BCAX) stock?

A

You can purchase shares of Bicara Therapeutics (NASDAQ:BCAX) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Bicara Therapeutics (BCAX) competitors?

Q

What is the forecast, or price target, for Bicara Therapeutics (BCAX) stock?

A

Bicara Therapeutics has a consensus price target of $32.50.

Q

What is the current price for Bicara Therapeutics (BCAX)?

A

The stock price for Bicara Therapeutics (NASDAQ: BCAX) is $22.81 last updated September 11, 2026 at 4:33 PM EDT.

Q

Does Bicara Therapeutics (BCAX) pay a dividend?

A

There are no upcoming dividends for Bicara Therapeutics.

Q

When is Bicara Therapeutics (NASDAQ:BCAX) reporting earnings?

A

Bicara Therapeutics does not have any upcoming earnings scheduled.

Q

Is Bicara Therapeutics (BCAX) going to split?

A

There is no upcoming split for Bicara Therapeutics.

Q

What sector and industry does Bicara Therapeutics (BCAX) operate in?

A

Bicara Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved